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Abstract Multiple sclerosis (MS) is an autoimmune, demye-
linating disease of the central nervous system. The protective
effects of melatonin (MLT) on various neurodegenerative dis-
eases, includingMS, have been suggested. In the present study,
we examined the effect of MLT on demyelination, apoptosis,
inflammation, and behavioral dysfunctions in the cuprizone
toxic model of demyelination. C57BL/6J mice were fed a chaw
containing 0.2 % cuprizone for 5 weeks and received two doses
of MLT (50 and 100 mg/kg) intraperitoneally for the last 7
days of cuprizone diet. Administration of MLT improved
motor behavior deficits induced by cuprizone diet. MLT
dose-dependently decreased the mean number of apoptotic
cells via decreasing caspase-3 and Bax as well as increasing
Bcl-2 levels. In addition, MLT significantly enhanced nuclear
factor-κB activation and decreased heme oxygenase-1 level.
However, MLT had no effect on interleukin-6 and myelin pro-
tein production. Our data revealed that MLT improved neuro-
logical deficits and enhanced cell survival but was not able to
initiate myelin production in the cuprizone model of demyelin-
ation. These findings may be important for the design of poten-
tial MLT therapy in demyelinating disorders, such as MS.
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Introduction
Multiple sclerosis (MS) is an autoimmune disease of the cen-
tral nervous system, which leads to myelin sheet breakdown
and neuronal loss [1]. Glial cell death, especially oligodendro-
cytes, has a critical role in the pathophysiology of MS [2].
According to different types of animal model of MS, feeding
with cuprizone, a copper chelating agent, can induce revers-
ible demyelination in different parts of the brain, especially in
the corpus callosum [3]. This toxic model of demyelination is
characterized by oligodendrocyte degeneration via copper-
dependent mitochondrial enzymes inhibition [4, 5]. Besides
oligodendrocyte death, astrogliosis as well as activated mi-
croglia and macrophages affect demyelination progression
by secreting pro-inflammatory cytokines [5]. Blood brain bar-
rier (BBB) remains intact during cuprizone treatment and
therefore local damage occurs without contribution of im-
mune system and lymphocytes infiltration [6].
Melatonin (MLT; N-acetyl-5-methoxytryptamine) is an en-
dogenous hormone, which is mainly secreted by the pineal gland
[7]. Besides its well-known functions, such as controlling the
circadian rhythm, it has been suggested that MLT has neuropro-
tective properties bymodulation of oxidative stress, neuroinflam-
mation, mitochondrial homeostasis, and apoptosis [8]. This hor-
mone has a high lipophilicity with excellent biomembrane per-
meability that enables it to freely cross the BBB.After exogenous
administration, MLT was found in high concentrations in the
brain [9]. In addition, MLT can reach subcellular compartments
through its two types of receptors: i) G-protein couple receptors
(MT1, MT2) that can initiate intracellular signal transduction
cascades [10, 11] and ii) quinone reductase enzyme family
(MT3), which has binding site for selective agonists and
antagonists as well as similar affinity to MLT and its
precursor, N-acetylserotonin [12].
MLT neuroprotective effects have been reported by several
experimental investigations. It has been suggested that MLT has
an anti-apoptotic effect in some neurodegenerative diseases, like
Alzheimer’s disease, stroke, and Huntington’s disease [13]. Fur-
thermore, MLT can reduce acute and chronic inflammation by
decreasing pro-inflammatory cytokines and modulating serum
inflammatory parameters [13, 14]. MLTadministration increased
fibers myelination and oligodendrocytes maturation by decreas-
ing white matter inflammation after neonatal stroke [9] and ex-
hibited an anti-nociceptive action in an animal model of acute
pain [15]. In experimental autoimmune encephalomyelitis (EAE)
model, MLT ameliorates the severity of paralysis accompanied
by less spinal cord infiltration of inflammatory cells [16]. Fur-
thermore, increases in serummelatonin concentrations have been
suggested as a possible mechanism underlying the effectiveness
of some drugs in treatment ofMS [17]. The aim of this studywas
to examine the effects of MLT on behavioral changes as well as
molecular and histopathological alterations in cuprizone toxic
model of demyelination.
Materials and Methods
Animals and Demyelination
Male C57BL/6 mice with body weight ranging between 20
and 25 g (8 to 9 weeks old) were obtained from Pasteur Insti-
tute, Tehran, Iran. They were maintained on a 12-h light/dark
cycle in room temperature between 20 and 22 °C and had free
access to food and water. To induce demyelination, mice were
fed with a diet containing 0.2 % cuprizone mixed into ground
standard rodent chow for 5 weeks. Control animals were fed
normal powdered chow. All animal manipulations were car-
ried out according to the Ethical Committee for the use and
care of laboratory animals of Tehran University of Medical
Sciences and Shefa Neuroscience Research Center.
Experimental Design
Mice were divided randomly into 4 groups: (i) control group
which received normal powdered chow for 5 weeks with in-
traperitoneal (i.p.) injection of ethanol 1 % (diluted in saline)
for 7 days, (ii) cuprizone group that were fed powdered chow
mixed with 0.2 % cuprizone for 5 weeks, (iii) MLT group
which were divided into 2 separated subgroups, treated with
50 or 100 mg/kg of MLT (i.p.) injected in midday for the last
7 days of 5 weeks cuprizone feeding, and (iv) healthy group
which were divided into 2 subgroups which received 2 doses
of MLT (50 and 100 mg/kg) separately in midday for 7 days.
All mice from different groups were evaluated via behavioral,
molecular, and histopathological tests.
Behavioral Experiments
Open-Field Test
To evaluate the effect ofMLTonmotor impairment, all groups
were assessed by open-field test at the end of the 5th week of
experiment. Animals (each group, n=7) were placed in an
open-field box, and locomotion was tracked over a 3-min
period. The EthoVision tracking system (Noldus Information
Technology, Wageningen, The Netherlands) was used to eval-
uate motor function by measuring the total distance moved
(cm) and velocity (cm/s); [18, 19].
Tail-Flick Test
A standardized tail-flick apparatus (tail-flick Unit 7360, Ugo
Basile, Italy) with a radiant heat source connected to an auto-
matic timer was used to assess acute nociception response.
After the end of the 5th week, each animal was placed in a
restrainer and the tail-flick latency was measured by focusing
a beam of light on the distal 2 cm of the tail until the animal
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exhibited a flick of the tail. Cut-off time (10 s) was used to
minimize tissue damage [20].
Western Blot Analysis
For Western blot analysis, the caudal region of the corpus
callosum was dissected from the brain. Samples were homog-
enized and centrifuged at 12000 rpm for 20 min with lysis
buffer containing a complete protease inhibitor cocktail.
Bradford’s method was used to determine protein concentra-
tions [21]. Bovin serum albumin was considered for generat-
ing standard plot. In the next step, total proteins were separat-
ed in 12 % SDS PAGE gels electrophoretically and after trans-
ferring to polyvinylidene-fluoridemembranes, probedwith spe-
cific antibodies. Immunoreactive peptides were detected by
chemiluminescence using enhanced electrochemiluminescence
(ECL) reagents (Amersham Bioscience) and subsequent auto-
radiography. Results were quantified by densitometric scan of
films, and data analysis was done using ImageJ, measuring
integrated density of bands after background subtraction. Nu-
clear and cytoplasmic proteins were isolated as described [22].
Histopathological Studies
Ketamine (i.p, 50 mg/kg) and xylazine (4 mg/kg) were used
for mice anesthesia after the 5th week of experiment. There-
after, mice were perfused with 4 % paraformaldehyde (PFA).
Brains were dissected, post-fixed in 4 % PFA, and embedded
in paraffin for 24 h. Finally, coronal sections were obtained in
6-μm thickness from 1.58–2.30 mm from the bregma).
For assessing myelination, Luxol Fast Blue (LFB) staining
was used for paraffin sections. Briefly, after anhydration, brain
sections were incubated with 0.1 % LFB solution at 60 °C
during the night. The slides were differentiated in lithium car-
bonate solution for 30 s and then in 70 % ethyl alcohol for
another 30 s after rinsing with 95%, 70% ethanol and distilled
water. Following another wash with distilled water, the sec-
tions were counterstained with 0.1 % cresyl fast violet for 10 s.
Thereafter, sections were washed with distilled water,
dehydrated in a graded series of alcohols, cleared in xylene,
and finally mounted [23]. The ventral body of the corpus
callosum was observed with an Olympus light microscope
(BX51, Olympus, Japan) and photographed with an Olympus
digital camera (Olympus, Japan) linked to a microscope.
ImageJ software was used to evaluate the extent of demyelin-
ation based on the ratio of blue to pink fibers in the corpus
callosum as the percentage of volume fraction in damage
tissue/total area for 16 sections in each animal (n=4). Further-
more, hematoxylin and eosin (H&E) staining was performed
to evaluate inflammation.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL) test was used for staining DNA
fragmentation using an in situ Cell Death Detection Kit (Roche,
Germany) to evaluate DNA fragmentation. Three 6-μm-thick
tissue sections were dewaxed from each block, dehydrated by
60 °C heating, with a following washing in xylene. Thereafter,
sections were rehydrated through washing with diluted alcohol.
After being washed with 10 mM Tris-HCl (pH 7.6), incubation
in methanol was performed for tissue sections containing 0.3 %
H2O2 for 10 min to inhibit endogenous peroxidase activity.
They were then treated with proteinase K (Roche, 20 μg/ml
in Tris buffer) at 37 °C for 30 min, incubated in TUNEL reac-
tion mixture (450 μl of label solution and 50 μl of enzyme
solution) at 37 °C for 60 min and in POD solution for
30 min. The color reaction was developed in 3-3’–diaminoben-
zidine (DAB, Roche; 0.5 μl DAB and 1.5 μl peroxide buffer)
for 5–10 min with cresyl violet counterstaining. The percentage
of TUNEL-positive neurons was calculated by counting 500
cells in each specimen (five visual fields/specimen). Sections
were examined on an Olympus microscope (CX31, Tokyo,
Japan) with a ×40 objective lens and images were captured
using a digital camera (Olympus, Japan); [24, 25].
Drugs
MLT, ketamine, and xylazine were purchased from Sigma-Al-
drich. Antibodies directed against β-actin, nuclear factor-κB
(NFκB), caspase-3, and Bax and Bcl-2 were obtained from Cell
Signaling Technology. Lamin-B2, interlukein-6 (IL-6),
proteolipid protein (PLP), and peripheral myelin protein 22
(PMP-22) antibodies were purchased from Santa Cruz Biotech-
nology. Heme oxygenase-1 (HO-1) antibody was obtained from
ABCAM. ECL kit was obtained from Amersham Bioscience.
Ethanol and cresyl fast violet were purchased from Merck, and
Cell Death Detection Kit was obtained from Roche. MLT was
initially dissolved in ethanol and diluted to a concentration of 1%
ethanol.
Statistical Analysis
For all experiments, datawere analyzed usingGraphPad Prism 5.
Comparison between groups was tested by one-way analysis of
variance (ANOVA) followed by Newman-Keuls post hoc test.
Statistical significances were gained when p <0.05.
Results
The Effect of MLT on Animal Movement
In the current study, cuprizone and MLT groups were fed a diet
containing 0.2% cuprizone for 5weeks. Two doses ofMLTwere
injected (i.p.) for the last 7 days of cuprizone feeding. The day
after, animals were investigated by open-field test for distance
moved and movement velocity. Cuprizone feeding significantly
decreased distance moved and movement velocity compared to
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the control group (n=6). Two different concentrations of MLT
dose-dependently enhanced distance moved and movement ve-
locity in mice affected by cuprizone alone compared to the
cuprizone group (n=12, Fig. 1 a, b). MLT alone did not affect
these parameters in the healthy group (n=6).
The Effect of MLT on Nociception
The analgesic effect of two doses of MLT on cuprizone model
was assessed by tail-flick test. The acute nociception latency was
evaluated the day after 5 weeks of cuprizone diet. As Fig. 2
shows, cuprizone feeding did not change the nociception latency
(n=6) but application of MLTat both 50 and 100 mg/kg in these
mice dose-dependently and significantly increased the
nociception latency (n=6). However, MLT alone in healthy ani-
mals had no significant effect on nociception response (n=6).
The Effect of MLT on Apoptotic Markers
Cuprizone diet increased Bax to Bcl-2 ratio, a key factor in the
regulation of apoptosis, indicating that apoptosis enhanced via
Bax upregulation (n=6). MLT administration dose-dependently
diminished this ratio, confirming MLT anti-apoptotic effect in
cuprizone model of demyelination (n=12). MLT alone did not
show any changes in Bax/Bcl-2 ratio in the healthy group (n=6,
Fig. 3a). After 5 weeks of cuprizone diet, cleaved active caspase-
3 level significantly increased, indicating its involvement in oli-
godendrocytes apoptosis (n=6). MLT administration dose-
dependently diminished caspase-3 (n=12, Fig. 3b). Injection of
MLT did not alter caspase-3 level in the healthy group (n=6).
Based on TUNEL assay, the mean number of TUNEL-positive
cells significantly increased after 5 weeks of cuprizone diet (n=
6). MLT treatment only at 100 mg/kg significantly diminished
the mean number of TUNEL-positive cells in the medial region
of the corpus callosum compared to the cuprizone group (n=6,
Fig. 3c).
The Effect of MLT on NFκB, IL-6, and HO-1 Level
A significant increase in nucleus NFκB levels occurred after
5 weeks of cuprizone diet compared to the control group (n=
6). Application of MLT, however, did not reduce NFκB levels.
MLT administration dose-dependently increased NFκB level
(n=12, Fig. 4a). MLT did not affect NFκB levels in the healthy
mice group (n=6). The level of IL-6 increased after 5 weeks of
cuprizone diet compared to control mice. However, application
of MLT for the last 7 days of cuprizone feeding did not change
IL-6 level compared to the cuprizone group (n=12). Further-
more, the healthy group receiving MLT did not show any differ-
ences in IL-6 level compared to control mice (n=6, Fig. 4b). HO-
1 value significantly decreased following 5 weeks of cuprizone
diet. Additionally, administration of MLT dose-dependently di-
minished its amount compared to the cuprizone group. MLT
alone did not affect HO-1 level in healthy mice when compared
to the control group (n=6, Fig. 4c). In H&E staining,
Fig. 1 Effect of two different concentrations of melatonin (MLT) on
behavior of cuprizone (CUP)-treated mice at the open-field test. Mice
treated by MLT at 50 mg/Kg (##p 0.01) and 100 mg/Kg (###p 0.001)
during the last 7 days of a 5-week CUP treatment traveled longer
distances (a) at higher velocities (b). Data represent the mean±S.E.M.
Fig. 2 The effect of cuprizone (CUP) application and intraperitoneal
injection of different concentrations of melatonin (MLT) on the tail-flick
test. Administration of CUP did not induce any significant effect on
nociceptive responses compared to control mice. MLT also did not alter
nociceptive responses in control mice. However, application ofMLTat 50
and 100 mg/Kg during the last 7 days of a 5-week CUP treatment
significantly increased the nociception latency compared to other
animal groups (##p 0.01). Data represent the mean±S.E.M.
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Fig. 3 Effect of two different concentrations of melatonin (MLT) on
apoptotic markers in cuprizone (CUP)-treated mice. Using Western blot
technique, the effects of MLTat different concentrations (50 and 100 mg/
Kg) on Bax/Bcl-2 ratio (a) and caspase-3 activation (b) were tested in
mice treated with CUP for 5 weeks. The densities of Bax, Bcl-2 (a), and
caspase-3 (b) bands were measured, and their ratio to β-actin was
calculated. ***p 0.001 represents difference from control group,
##p 0.01 and ###p 0.001 represent differences from the cuprizone
group. Values indicate mean±S.E.M. The number of apoptotic cells
was evaluated by TUNEL test (c). TUNEL-positive cells were
significantly increased in the cuprizone group compared to control mice
(**p 0.01). MLT at a concentration of 100 mg/kg significantly decreased
the mean number of TUNEL-positive cells compared to the cuprizone
group (##p 0.01). Data are given as mean±S.E.M. Scale bar equals
50 μm (×40)
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hematopoietic cell infiltration as an indicator of tissue inflamma-
tion was assessed. Our data showed a significant increase in
hematopoietic cells after 5 weeks of cuprizone diet compared
to the control group. MLT injection did not significantly affect
hematopoietic cell infiltration compared to the cuprizone group
(n=6, Fig. 4d).
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Fig. 4 Effect of two different concentrations of melatonin (MLT) on
NFκB, IL-6, and HO-1 levels in cuprizone-treated mice. Western blot
technique was used to study the effects of MLT at different
concentrations (50 and 100 mg/Kg) on NFκB (a), IL-6 (b), and HO-1
(c) levels in the corpus callosum in mice treated with BUC. The densities
of NFκB (a), IL-6 (b), and HO-1 (c) bands were measured, and their
ratios to Lamin-B2 for NFκB and β-actin for IL-6 and HO-1 were
calculated. ***p 0.001 represents difference from control group,
#p 0.05 and ##p 0.01 represent difference from the cuprizone group.
The effect of MLT on the number of hematopoietic cells in the corpus
callosumwas evaluated by hematoxylin and eosin staining (d). The mean
number of hematopoietic cells was significantly increased in the
cuprizone group compared to control mice (*p 0.05). There was no
statistically significant difference among MLT groups and cuprizone in
the number of hematopoietic cells. Data represent mean±S.E.M. Scale
bar equals to 50 μm (×40)
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The Effect of MLT on Myelination
PLP (central nervous system (CNS)-specific myelin protein)
and PMP-22 are myelin sheet proteins that were considered as
indicators of myelination process. According to Fig. 5,
cuprizone diet significantly decreased the amount of these
proteins after application for 5 weeks (n=6, Fig. 5a, b). How-
ever, neither MLTadministration in cuprizone-treated animals
(n=12) nor MLT injection to healthy animals (n=6) could
increase myelin protein levels. In order to show demyelination
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Fig. 5 Effect of two different concentrations of melatonin (MLT) on
myelin proteins in cuprizone (CUP)-treated mice. Using Western blot
analysis, the effects of MLT at different concentrations (50 and 100 mg/
Kg) onmyelin proteins PLP (a) and PMP-22 (b) were tested in mice treated
with CUP. The densities of PLP (a) and PMP-22 (b) bands were measured,
and their ratios toβ-actin were calculated. ***p 0.001 represents difference
from the control group. The severity of demyelination in the corpus
callosum was evaluated with LFB staining (c). The blue areas show
intact region (in the control group) whereas the pink areas show
demyelinating areas. There is no statistically significant difference among
MLT groups and cuprizone in the severity of demyelination. Percentage in
volume fraction in damage tissue/total area was measured for 16 sections in
each animal. Scale bar 50 μm (×10)
Mol Neurobiol (2016) 53:4675–4684 4681
severity, LFB staining was used to evaluate percentage of
volume fraction. Cuprizone diet significantly decreased mye-
lin protein levels, compared to control mice (n=6). MLT did
not increase this level compared to the cuprizone group (n=
12, Fig. 5c).
Discussion
In the current study, the effects of MLTon behavioral deficits,
apoptosis, and inflammation induced by 5 weeks of cuprizone
diet were investigated. A significant demyelination was de-
tectable after 3 weeks of cuprizone treatment along with pri-
mary oligodendroglia apoptosis and microglia activation
while maximum demyelination was observed after 5 weeks
[4]. Our results that showed 5 weeks cuprizone feeding de-
clined distance moved and velocity in mice is in agreement
with another study in which cuprizone induced motor skills
and behavioral dysfunctions [26]. MLT injection improved
distance moved and velocity in cuprizone-fed animals. It has
been previously shown that higher MLT plasma concentration
was accompanied by improvement of general condition ofMS
patients [27], and MLT reduced the severity of paralysis
in the EAE model of demyelination [16]. Protective ef-
fect of MLT on motor recovery was also reported after
spinal cord injury in mice [17].
In this study, cuprizone diet did not change pain threshold
examined by Tail-flick test. This indicates that somatosensory
neurons were probably not affected by cuprizone toxic effect.
However, MLT administration raised nociception latency in
cuprizone-treated animals, suggesting anti-nociceptive effect
of MLT in this model. Anti-nociceptive effect of MLT has
been shown at spinal and supraspinal levels [28]. This effect
lasts over hours due to MLT short half-life [29]. However, our
results showed long acting anti-nociceptive effect of MLT,
suggesting that MLT might probably stimulated other path-
ways that have long lasting anti-nociceptive effect [30]. Fur-
thermore, it has been shown that some analgesics are not ef-
fective in the reduction of nociceptive responses evoked in
normal condition but it is effective in a situation of central
sensitization [31].
This finding was in line with other studies indicating that
MLT prevented induction of TUNEL-positive cells in neuro-
nal tissues [32, 33]. Three proteins that play major roles in
regulating apoptosis were investigated: Bcl-2 as well as Bax
from B cell lymphoma related family proteins, known to have
a major role in the regulation of mitochondrial membrane
permeability [34], and caspase-3, well-known as a down-
stream executioner caspase of caspase-dependent apoptotic
cascades [35]. Using various experimental models, several
studies revealed that MLT could block caspase-3 activation
[36], increase Bcl-2 anti-apoptotic protein level [37, 38], and
diminish Bax pro-apoptotic protein [37]. Our data revealed an
increase of caspase-3 level after 5 weeks of cuprizone diet.
Activated caspase-3 expressed in oligodendrocytes plays a
crucial role in cell death in the EAE model of demyelination
[39]. MLTwas previously shown to be a powerful antioxidant
that decreases caspase-3 activity [36]. In our study, adminis-
tration of MLT prevented induction of apoptotic cells and
reduced caspase-3, suggestingMLTability to inhibit apoptosis
via intrinsic pathway. Furthermore, MLT decreased Bax level
versus a significant increase in Bcl-2 amount, which results in
Bax/Bcl-2 ratio regulation in neuronal tissues [37, 38]. Our
results revealed that cuprizone feeding increased Bax/Bcl-2
ratio, an effect that was counteracted by application of MLT.
This suggests the ability of MLT to regulate cuprizone-
induced apoptosis via the mitochondrial-dependent intrinsic
pathway [39]. Besides its direct effect on apoptotic and anti-
apoptotic markers, it has been reported that MLT might de-
crease apoptosis via regulating the function of mitochondrial
complex, which leads to reduction of electron leakage and
generation of free radicals [40].
There are several studies which report activation of astro-
cyte NFκB leads to oligodendrocyte death under cuprizone
diet [2, 41]. In this study, nuclear NFκB levels were evaluated
using Western blot technique. Activation of astrocytes in dif-
ferent conditions, such as cuprizone feeding, leads to NFκB
upregulation and oligodendrocyte death [34, 42]. In the cur-
rent study, NFκB level increased after cuprizone diet and ad-
ministration of MLT further increased its level. Antithetical
results were reported onMLTeffect on inflammatory process-
es. While some investigations point to anti-inflammatory ef-
fect of MLT [8, 14, 43], some other studies reported stimulat-
ing pro-inflammatory cytokines release [44, 45] and activating
NFκB translocation [1] after administration of MLT. Several
different factors, such as the stage of inflammation, patholog-
ical conditions in which several cell parameters are changed,
and different levels of action or targets ofMLT, may determine
anti- or pro-inflammatory effects of MLT [46–48].
It has been suggested that activation of NFκB is critical for
cell survival after MLT application [46]. HO-1 is one of the
isoforms of HO, a microsomal enzyme, which is expressed at
low levels under basal conditions but can be produced in high
amounts in oxidative stress and acts as an antioxidant and anti-
inflammatory agent [49]. Cuprizone diet, in our study, dimin-
ished HO-1 level, and MLT further decreased its amount. It
has been reported that activation of NFκB can suppress the
expression of antioxidant genes by indirectly downregulating
HO-1 [50].
MLT has a potent protective effect on white matter by
reduction of microglial activation and subsequently enhancing
oligodendroglial maturation and myelination [9, 14]. In this
study, the amount of myelin proteins (both PLP and PMP-22)
diminished after cuprizone feeding. MLT administration,
however, did not change the myelin protein levels and myelin
volume fractions. This suggests that MLT does not have an
4682 Mol Neurobiol (2016) 53:4675–4684
impact on demyelination/remyelination process in the
cuprizone model. Evidence from patients suffering from MS
suggests that demyelination alone is insufficient to explain the
loss of neurologic functions, including motor function impair-
ments, associated with the disease. A combination of
oligodendrogliopathy and axonopathy has been predicted as
the main pathophysiology of neurologic dysfunction in MS
[51]. Experimental investigations also revealed that demyelin-
ation is necessary but insufficient for axon injury and loss of
neurologic function in an animal model of MS [52]. Axonal
pathology, as a possible consequence of oligodendrocyte in-
flammation, is not limited to demyelinated lesions but extends
into normal-appearing white matter and contributes to neuro-
logical deficits [53]. However, it should be noted that in con-
trast to our study, application of MLT at 5 mg/kg reversed
cuprizone-induced demyelination in adult male mice [54].
In the present study, MLT was ineffective in triggering
myelination but improve motor function and enhanced cell
survival in cuprizone toxic model of demyelination. Since
oligodendrocytes are highly vulnerable in an inflammatory
context [51, 52], MLT may enhance oligodendrocyte survival
by reducing white matter inflammation [9, 14] and subse-
quently promotes axonal regeneration and improves neurolog-
ical deficits [55] in demyelinating disorders, such as MS.
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